GlassScriptPhysician profile
Ebu Scohy
NPI 1861487027
$7,562.49
in general payments reported to CMS, 2019-2025
24 companies · $2,973 in 2025
The $2,973 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.10 · 2022: $243 · 2023: $1,805 · 2024: $2,459 · 2025: $2,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,121 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,121.19 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,571.78 | 2022-2025 | |
| Genzyme Corporation | $826.59 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $656.81 | 2023-2025 | Zoryve |
| Incyte Corporation | $647.09 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $622.96 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $361.07 | 2023-2025 | |
| Organon LLC | $353.15 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $341.65 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $305.26 | 2023-2025 | Absorica Ld, Winlevi |
| Ucb, INC. | $281.88 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $276.81 | 2024-2025 | Tremfya |
| Amgen INC. | $225.67 | 2023-2024 | Otezla |
| Merz North America, INC. | $219.58 | 2025 | |
| Novartis Pharmaceuticals Corporation | $189.10 | 2023-2025 | |
| Galderma Laboratories, L.P. | $179.23 | 2024-2025 | Nemluvio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $163.51 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $111.78 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $73.87 | 2024-2025 | Sotyktu |
| Almirall LLC | $45.95 | 2023 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.77 | 2025 | Spevigo |
| Botanix Sb INC | $23.68 | 2025 | Sofdra |
| Ani Pharmaceuticals, INC. | $23.24 | 2025 | Veregen |
| Biofrontera INC. | $19.28 | 2025 | Ameluz |
| Strata Skin Sciences, INC. | $16.78 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebu Scohy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.